Literature DB >> 22152498

Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease.

Miranda C E Lomer1, William B Cook, Hamid Jan B Jan-Mohamed, Carol Hutchinson, Ding Yong Liu, Robert C Hider, Jonathan J Powell.   

Abstract

Fe deficiency and Fe-deficiency anaemia are common in patients with inflammatory bowel disease (IBD). Traditional clinical markers of Fe status can be skewed in the presence of inflammation, meaning that a patient's Fe status can be misinterpreted. Additionally, Fe absorption is known to be down-regulated in patients with active IBD. However, whether this is the case for quiescent or mildly active disease has not been formally assessed. The present study aimed to investigate the relationship between Fe absorption, Fe requirements and standard haematological indices in IBD patients without active disease. A group of twenty-nine patients with quiescent or mildly active IBD and twenty-eight control subjects undertook an Fe absorption test that measured sequential rises in serum Fe over 4 h following ingestion of 200 mg ferrous sulphate. At baseline, serum Fe, transferrin saturation, non-transferrin-bound Fe (NTBI), ferritin and soluble transferrin receptor were all measured. Thereafter (30-240 min), only serum Fe and NTBI were measured. Fe absorption did not differ between the two groups (P = 0·9; repeated-measures ANOVA). In control subjects, baseline haematological parameters predicted Fe absorption (i.e. Fe requirements), but this was not the case for patients with IBD. Fe absorption is normal in quiescent or mildly active IBD patients but standard haematological parameters do not accurately predict Fe requirements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22152498      PMCID: PMC3378490          DOI: 10.1017/S0007114511004971

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  28 in total

1.  Correlation between diagnostic 59Fe2+-absorption and serum ferritin concentration in man.

Authors:  H C Heinrich; J Brüggemann; E E Gabbe; M Gläser
Journal:  Z Naturforsch C Biosci       Date:  1977 Nov-Dec

2.  Serum soluble transferrin receptor in hypochromic microcytic anaemia.

Authors:  S Jayaranee; P Sthaneshwar
Journal:  Singapore Med J       Date:  2006-02       Impact factor: 1.858

3.  Serum non-transferrin-bound iron and low-density lipoprotein oxidation in heterozygous hemochromatosis.

Authors:  Lambertus J H van Tits; Esther M G Jacobs; Dorine W Swinkels; Heidi L M Lemmers; Gerly M van der Vleuten; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Biochem Biophys Res Commun       Date:  2006-05-02       Impact factor: 3.575

4.  Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo.

Authors:  T M Rooyakkers; E S G Stroes; M P Kooistra; E E van Faassen; R C Hider; T J Rabelink; J J M Marx
Journal:  Eur J Clin Invest       Date:  2002-03       Impact factor: 4.686

5.  Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.

Authors:  M P Kooistra; S Kersting; I Gosriwatana; S Lu; J Nijhoff-Schutte; R C Hider; J J M Marx
Journal:  Eur J Clin Invest       Date:  2002-03       Impact factor: 4.686

6.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

7.  Iron deficiency in inflammatory bowel disease. Diagnostic efficacy of serum ferritin.

Authors:  A B Thomson; R Brust; M A Ali; M J Mant; L S Valberg
Journal:  Am J Dig Dis       Date:  1978-08

8.  Non-transferrin-bound iron in plasma following administration of oral iron drugs.

Authors:  Bernd Dresow; Doerte Petersen; Roland Fischer; Peter Nielsen
Journal:  Biometals       Date:  2007-09-13       Impact factor: 2.949

9.  Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease.

Authors:  Irit Maor; Tova Rainis; Amos Lanir; Alexandra Lavy
Journal:  Dig Dis Sci       Date:  2008-02-06       Impact factor: 3.199

10.  Serum iron curves can be used to estimate dietary iron bioavailability in humans.

Authors:  Rana E Conway; Catherine A Geissler; Robert C Hider; Richard P H Thompson; Jonathan J Powell
Journal:  J Nutr       Date:  2006-07       Impact factor: 4.798

View more
  14 in total

1.  Maresin 1 ameliorates iron-deficient anemia in IL-10(-/-) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway.

Authors:  Honggang Wang; Peiliang Shi; Chuanjiang Huang; Qinghong Liu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide.

Authors:  Fernando Gomollón; Javier P Gisbert
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  Convergence of nanotechnology and cancer prevention: are we there yet?

Authors:  David G Menter; Sherri L Patterson; Craig D Logsdon; Scott Kopetz; Anil K Sood; Ernest T Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-24

Review 4.  Anaemia in inflammatory rheumatic diseases.

Authors:  Günter Weiss; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

Review 5.  Iron deficiency anemia in inflammatory bowel disease.

Authors:  Sindhu Kaitha; Muhammad Bashir; Tauseef Ali
Journal:  World J Gastrointest Pathophysiol       Date:  2015-08-15

Review 6.  Management of iron deficiency anemia in inflammatory bowel disease - a practical approach.

Authors:  Jürgen Stein; Axel U Dignass
Journal:  Ann Gastroenterol       Date:  2013

Review 7.  Anemia in inflammatory bowel disease: an under-estimated problem?

Authors:  Gerhard Rogler; Stephan Vavricka
Journal:  Front Med (Lausanne)       Date:  2015-01-19

8.  Iron status is inversely associated with dietary iron intakes in patients with inactive or mildly active inflammatory bowel disease.

Authors:  Jonathan J Powell; William B Cook; Mark Chatfield; Carol Hutchinson; Dora Ia Pereira; Miranda Ce Lomer
Journal:  Nutr Metab (Lond)       Date:  2013-02-01       Impact factor: 4.169

9.  Dietary fortificant iron intake is negatively associated with quality of life in patients with mildly active inflammatory bowel disease.

Authors:  Jonathan J Powell; William B Cook; Carol Hutchinson; Zoe Tolkien; Mark Chatfield; Dora Ia Pereira; Miranda Ce Lomer
Journal:  Nutr Metab (Lond)       Date:  2013-01-15       Impact factor: 4.169

10.  Ferroportin mediates the intestinal absorption of iron from a nanoparticulate ferritin core mimetic in mice.

Authors:  Mohamad F Aslam; David M Frazer; Nuno Faria; Sylvaine F A Bruggraber; Sarah J Wilkins; Cornel Mirciov; Jonathan J Powell; Greg J Anderson; Dora I A Pereira
Journal:  FASEB J       Date:  2014-04-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.